Company intelligence / Profile preview

Asimov

Boston, Massachusetts, United Statesasimovonline.com ↗

Ownership: Private
Employees: ~70
Development stage: Other

Overview

Asimov does not have its own clinical pipeline but provides advanced synthetic biology platforms that enable partners to develop next-generation therapeutics. Its technologies have demonstrated high titers in protein expression systems and robust performance in cell/gene therapy production settings. No direct clinical results are published under the Asimov name.

Therapeutic areas: Other
Modalities: BiologicsCell therapyGene therapymRNA-based drugs
Industry: Non-Drug Biotech

Partnerships

Cytiva – collaboration on CHO Edge cell line development and process optimization for biologic manufacturingOver 25 partnerships with top pharmaceutical companies, biotechs & CDMOs globally

Beyond the preview

Go deeper on Asimov.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asimov.

Explore the full profile